2023
Hepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original ResearchTreatment initiationStage IHPB cancersStage I pancreatic cancerExtrahepatic bile duct cancerKaplan-Meier survival analysisHPB cancer patientsNational Cancer DatabaseRetrospective cohort studyBile duct cancerMedian treatment initiationHepatopancreatobiliary cancersMedian survivalCohort studyDuct cancerOverall survivalHispanic patientsEHBD cancerOncologic careBile ductCox regressionBlack raceCancer patientsDefinitive carePancreatic cancer
2019
Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population
Zarour LR, Billingsley KG, Walker BS, Enestvedt CK, Orloff SL, Maynard E, Mayo SC. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. The American Journal Of Surgery 2019, 217: 899-905. PMID: 30819401, DOI: 10.1016/j.amjsurg.2019.01.030.Peer-Reviewed Original ResearchConceptsSolitary hepatocellular carcinomaPrognostic nutritional indexHepatic resectionElderly patientsUnique diseaseLow prognostic nutritional indexMedian Child-Pugh scoreTumor size 5Child-Pugh scoreGrade III complicationsHalf of patientsRecurrence-free survivalSolitary HCCExtrahepatic recurrenceProspective databaseR0 resectionIntrahepatic recurrenceMajor hepatectomyMedian survivalOverall survivalViral hepatitisLow morbidityMedian ageClinicopathologic dataClinicopathologic differences
2010
Adjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model
2006
Current Status of Colorectal Cancer Therapy
Strother J, Billingsley K, Hung A, Blanke C. Current Status of Colorectal Cancer Therapy. 2006, 273-285. DOI: 10.1007/978-1-59745-172-7_23.Peer-Reviewed Original Research
2001
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population
Billingsley K, Maynard C, Schwartz D, Dominitz J. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 2001, 92: 1272-1280. PMID: 11571743, DOI: 10.1002/1097-0142(20010901)92:5<1272::aid-cncr1448>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsOperable esophageal carcinomaTrimodality therapyEsophageal carcinomaPerioperative mortalityDistal esophageal tumorsOutpatient clinic filesOutcomes of patientsRetrospective cohort studyOverall perioperative mortalityFavorable prognostic factorPredictors of survivalAbsence of metastasesMain outcome measuresPatient Treatment FileRecord Locator SystemType of treatmentHealth care systemInduction chemoradiotherapyMidesophageal tumorsNeoadjuvant chemoradiotherapyCohort studyMedian survivalOverall survivalPatient ageSurgical therapy